Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...

Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments.

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...